Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study observes how patients with mantle cell lymphoma fare on modern drugs

NCT ID NCT03816683

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study created a registry of 227 adults with mantle cell lymphoma who had recently started a new type of therapy. Researchers tracked which treatments were used, how long patients stayed on them, and how patients rated their own quality of life. The goal was to gather real-world information, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

227 people

The number who actually took part.

Started

Apr 2019

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a diagnosis of MCL who have received any line of novel MCL treatment within the past 6 months (and treatment is ongoing at the time of enrollment).

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient diagnosed with Mantle Cell Lymphoma (MCL) * Informed consent for participation * Age ≥ 18 years old, as of the first observed diagnosis of MCL * Patients for whom a clinical decision has been made to initiate novel therapy in the last 6 months, limited to the following novel agent categories: * Bcl-2 inhibitors * BTK inhibitors * Immunomodulatory agents * Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrollment. Exclusion Criteria: • Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mantle cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mantle cell lymphoma

Contacts and locations

Locations

  • Research Site

    Montgomery, Alabama, 36101, United States

  • Research Site

    Clovis, California, 93611, United States

  • Research Site

    Boulder, Colorado, 80303-1385, United States

  • Research Site

    Jacksonville, Florida, 32256, United States

  • Research Site

    Pensacola, Florida, 32503, United States

  • Research Site

    Tampa, Florida, 33612-9497, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Augusta, Georgia, 30912, United States

  • Research Site

    Chicago, Illinois, 60612, United States

  • Research Site

    Iowa City, Iowa, 52242, United States

  • Research Site

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    Duluth, Minnesota, 55805, United States

  • Research Site

    Saint Louis Park, Minnesota, 55416, United States

  • Research Site

    Saint Paul, Minnesota, 55102, United States

  • Research Site

    Lincoln, Nebraska, 68510, United States

  • Research Site

    Berkeley Heights, New Jersey, 07922, United States

  • Research Site

    Hackensack, New Jersey, 07601, United States

  • Research Site

    East Syracuse, New York, 13057, United States

  • Research Site

    New York, New York, 10022, United States

  • Research Site

    Eugene, Oregon, 97401-8122, United States

  • Research Site

    Danville, Pennsylvania, 17822, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Dallas, Texas, 75231, United States

  • Research Site

    Dallas, Texas, 75390, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    Seattle, Washington, 98122, United States

  • Research Site

    Seattle, Washington, 98195-9472, United States

  • Research Site

    Morgantown, West Virginia, 26506, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.